Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 5, 2012, Pages 653-663

  Dubbelman, Anne Charlotte ^a   Upthagrove, Alana ^b   Beijnen, Jos H ^a   Marchetti, Serena ^c   Tan, Eugene ^d   Krone, Kimberly ^b   Anand, Suraj ^d   Schellens, Jan H M ^c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Disposition; Dovitinib; Fibroblast growth factor receptor; Metabolism; Tyrosine kinase inhibitor; Vascular endothelial growth factor receptor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBON 14; DOVITINIB; DRUG METABOLITE; FIBROBLAST GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPNEA; ECG ABNORMALITY; ESOPHAGUS CANCER; FATIGUE; FEMALE; FIBROBLAST; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; LIQUID SCINTILLATION COUNTING; LUNG CANCER; MALE; MELANOMA; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLEURA CANCER; PRIORITY JOURNAL; RADIOACTIVITY; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SOLID TUMOR; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINOLONES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84871228425     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1947-2     Document Type: Article

References (14)

1. Dvorak HF (2003) Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 162:1747-1757. doi:10.1016/S0002-9440(10)64309-X
2. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J (2010) Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 8:1439-1452. doi:10.1158/1541-7786.MCR-10-0168
3. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116-129. doi: 10.1038/nrc2780
4. Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS (2008) Tumor escape from endogenous, extracellular matrix-Associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 14:1529-1539. doi:10.1158/1078-0432.CCR-07-4126
5. Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, Reynolds AR (2011) Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 30:1183-1193. doi:10.1038/onc.2010.503
6. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, Heise C (2005) In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 11:3633-3641. doi:10.1158/1078-0432.CCR-04-2129
7. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105:2941-2948. doi:10.1182/blood-2004-10-3913
8. André F, Bachelot TD, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turnere NS, Rugo HS, Baselga J, Zhang Y (2011) A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-Amplified metastatic breast cancer. J Clin Oncol 29(Suppl 15):Abstract 508
9. Angevin E, Grunwald V, Ravaud A, Castellano DE, Lin C, Gschwend JE, Harzstark AL, Chang J, Wang Y, Shi MM, Escudier BJ (2011) A phase II study of dovitinib (TKI258), an FGFR-And VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol 29(Suppl 15):Abstract 4551
10. Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM (2011) Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 17:7451-7461. doi:10.1158/1078-0432.CCR-11-1747
11. Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S, Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14:2075-2081. doi:10.1158/1078-0432.CCR-07-1466
12. Wang X, Kay A, Anak O, Angevin E, Escudier B, Zhou W, Feng Y, Dugan M, Schran H (2012) Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib. J Clin Pharmacol Jan 27 [epub ahead of print]
13. Hamilton RA, Garnett WR, Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413
14. Hartmann JT, Haap M, Kopp HG, Lipp HP (2009) Tyrosine kinase inhibitors -A review on pharmacology, metabolism and side effects. Curr Drug Metab 10:470-481